On June 28, 2009 Zynex hadcertain warrantsissued in 2004to purchase236,191shares of common stock issuedexpire. On September 26, 2009 Zynex hadstock options issued in 2004to purchasea total of 1.2 millionshares of common stockexpire. Earlier this yearwarrants to purchasea total of 120,000shares of common stockfrom three individual warrantholders also expired.

Thomas Sandgaard, CEO, commented: "The recently expired options and warrants represent approximately 15% of today'sfloat. We believe the expiration of options and warrants is valuable to shareholders because it reduces the potential dilution to shareholdershad these options and warrantsbeen exercised."

About Zynex

Zynex, Inc. (founded in 1996) engineers, manufactures, markets and sells its own design of electrotherapy medical devices in two distinct markets: standard digital electrotherapy products for pain relief and pain management; and the NeuroMove(TM) for stroke and spinal cord injury (SCI) rehabilitation. Zynex's product lines are fully developed, FDA-cleared, commercially sold, and have been developed to uphold the Company's mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain.

Safe Harbor Statement

Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital in order to grow our business, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers, acceptance of our products by hospitals and clinicians, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the uncertain outcome of pending material litigation and other risks described in our 10-K Report for the year ended December 31, 2008.

A service of YellowBrix, Inc.